Lilly and Boehringer say new diabetes drug met goals in trials
In the diabetes world, new drugs hold promise and hope.
And today, Eli Lilly & Co. and Boehringer Ingelheim announced that a new diabetes treatment called empagliflozin showed positive results over the course of four late-stage trials.
A new option for type 2 diabetics
The drug is for type 2 diabetics, and it helps to reduce blood glucose levels. In the trials, it helped produce significant changes in baseline HbA1c levels in patients who took 10- and 25-mg doses once a day.
The pharmaceutical partners are satisfied with the results.
"Boehringer Ingelheim and Lilly are encouraged by the efficacy and safety results for empagliflozin," said Prof. Klaus Dugi, senior vice president of medicine, Boehringer Ingelheim.
How it works
Instead of acting directly on insulin, empagliflozin helps to manage glucose in the kidneys, assisting the body in excreting it through urine.
In terms of side effects, the companies reported that genital infections occurred more in patients taking the drug than with those taking a placebo.
The drug is expected to go under regulatory review in the US, Japan and Europe this year, with detailed information being published about the trials this year and next.
"Many patients with type 2 diabetes are not meeting their blood sugar level goals, and alternative treatment options are needed for them," said Dugi. "We believe we are now one step closer to bringing a new treatment option to these patients."
Source: Fierce Biotech